



Interim Report

January – March 2025



LIDSTM

LIDDS AB (publ) Interim Report January – March 2024

First quarter 2024 (the Group)

- Net sales amounted to 0 (0) TSEK
- The operating result for the period was -1 254 (-1) TSEK
- The net result was -1 311 (-5) TSEK corresponding to earnings per share of -0,01 (-0.00) SEK
- Cash flow from operating activities amounted to -738 (-64) TSEK
- Cash and cash equivalents amounted to 4 768 (10 947) TSEK

Significant events after the reporting period (during April)

- On April 2, the board of directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202.
- Taking into account the principle of prudence, the board of directors, decided on April 10 to write down the book values of all intangible assets in LIDDS and Noviga as of 2024-12-31. This decision resulted in a deviation for the annual report compared to the published year-end report for 2024.
- Due to the reasons to believe that the company's equity was less than on-half of the registered share capital, the board of directors decided to prepare a balance sheet for liquidation purpose on April 22.
- The balance sheet for liquidation purpose prepared and reviewed by the company's auditor showed that the equity was less than half of the registered share capital and therefore the board of directors decided on April 24 to call a first control meeting.

Financial overview (the Group)

| KSEK | 1 January - 31 March 2025 | 1 January - 31 March 2024 | 1 January - 31 December 2024 |
|--|------------------------------|------------------------------|---------------------------------|
| Net sales | 0 | 0 | 0 |
| Operating result | -1 254 | -1 | -5 891 |
| Net result | -1 311 | -5 | -5 938 |
| Earnings per share, SEK | -0,01 | 0,00 | -0,05 |
| Cash flow from operating activities | -738 | -64 | -5 434 |
| Cash and cash equivalents by the end of the period | 4 768 | 10 947 | 5 506 |

LIDDS in Brief

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

CEO statement

During the first quarter, the focus has continued to be on trying to commercialize the three projects Nanoimod, Nanodotax and NOV 202. Furthermore, the work to reduce the company's costs has continued.

In beginning of April, we finally concluded, after extensive attempts, that Lidds will not succeed with the investments on which we have concentrated the company's resources on and therefore we did not see any opportunity to capitalize the company for further clinical studies. As a result, the board of directors decided to terminate further development of these project areas.

The work will now be fully focused on utilizing the values that the company owns in the form of the NanoZolid technology platform and its patents, the subsidiary Noviga with the drug candidate NOV 202 and its patents. In addition, we will investigate the interest for the company's listing on First North and any values for the accumulated loss carry forwards that have arisen.

Mats Wiking
CEO and CFO

Overview of activities

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has developed a proprietary drug delivery technology for local administration of drugs, NanoZolid. Several projects in the portfolio are based on the technology. In the portfolio there is also NOV202. The NanoZolid technology improves drug efficiency by allowing a more optimal dosage locally and at the same time reducing side effects, which is of great benefit to both patients and payers. LIDDS' technology can be used across different drug classes. LIDDS offers the NanoZolid technology to partners but has also done development within the oncology area. LIDDS' leading project is Liproca Depot, which has shown good effect in Phase IIb in treating prostate cancer patients. NOV202 is a pre-clinical asset which has been developed for advanced cancer. NOV202 has shown promising synergistic anti-tumour effect together with PARP inhibitors in several tumour models. Examples of preclinical cancer models used are models for ovarian-, pancreatic- and prostate cancer. The aim has been to secure licensing deals for internally developed projects and for the technology as such.

NanoZolid improves efficacy and reduces side-effects

NanoZolid addresses some of the challenges that conventional drugs face, such as systemic side effects and limited efficacy. The NanoZolid-formulated drug is delivered locally through an injection and forms a solid and safe depot that releases the active drug over a period of up to six months. The controlled release of drug compounds can be tailored to specific needs and the drugs being used. This results in a more precise treatment with fewer side effects.

LIDDS' portfolio is focused on oncology where the benefits of the technology are obvious

LIDDS' own development has been focused on the oncology therapeutic area, where the benefits of the NanoZolid technology are obvious: a local and high drug dose that is administered over time with very limited side effects. The company has developed Nanodotax, a NanoZolid formulated cytotoxic drug (docetaxel), and Nanoimod, a combination therapy with checkpoint inhibitors. Both projects are in clinical phase.

Enables lower development costs for partners

NanoZolid drug delivery technology offers benefits for potential partners. There is an opportunity to extend the commercial life of already existing products and to improve efficacy and reduce side-effects. A reformulation of an existing drug also means lower development costs and risks and shorter time to market.

LIDDS oncology pipeline

Nanodotax

Nanodotax is NanoZolid-formulated docetaxel which is a commonly used chemotherapeutic drug that has been approved for several oncological conditions and on the market since 1996. Nanodotax has shown to be safe and well tolerated in a Phase I study where adverse events were shown to be mild and local. Furthermore, there was an observed effect on systemic immunological biomarkers indicating that the immune system was responding positively and specifically to the drug. The project is Phase Ib ready on prostate cancer patients.

Nanoimod

Nanoimod is the toll-like receptor 9 (TLR9) agonist agatolimod formulated in NanoZolid. The project is in preclinical development and has been prepared for a Phase Ib clinical study in malign melanoma in addition to treatment with Checkpoint inhibitors.

NOV202

NOV202 is a small molecule developed for treatment of advanced cancer. NOV202 is in pre-clinical development and is being prepared for 28-day regulatory toxicity study and safety pharmacology study.

Significant events after the reporting period

Decision to cease further development

On April 2, the Board of Directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202. The board concluded, after extensive trials, that the company will not succeed with the investments on which the company's resources has been concentrated and therefore it will not be possible to capitalizing the company for clinical studies.

Decision to write-down intangible assets

Following the board's decision on April 2, and considering the principle of prudence, the board decided on 10 April to write down the book values of intangible assets regarding development work and patents. Since the write-downs were made as of the year-end 2024/2025, this decision resulted in a deviation for the annual report compared to the earlier published year-end report 2024.

Decision to prepare a balance sheet for liquidation purpose

Due to the fact that there was reason to assume that the company's equity was less than half of the registered share capital, the board decided to prepare a balance sheet for liquidation purpose on April 22.

Balance sheet for liquidation purposes

The prepared balance sheet for liquidation purposes did show that company's equity was less than half of the registered share capital and therefore the board convened a first control meeting. In connection with the notice of the annual general meeting on May 28, the first control meeting for LIDDS was also called.

Financial information

Acquisition of Noviga Research AB

LIDDS acquired all shares in Noviga Research AB through an issue in kind. The acquisition has been classified as a reverse takeover, which means the former owners of Noviga Research AB has the controlling influence on LIDDS. The purchase price was 10.3 MSEK, corresponding to 68,231,663 shares in LIDDS. The accounting effect is a negative goodwill. The classification also means that Noviga Research will be parent company in the group and comparative figures are missing for the group. The comments to sales and result below is for the legal parent company LIDDS AB.

Net sales and result for the first quarter 2025

During the first quarter of 2025, net sales amounted to SEK 0 (0) MSEK. The operating profit for the first quarter of 2025 amounted to SEK -1.1 (-2.5) MSEK. In principle, all costs have decreased compared to the first quarter of 2024, but the largest decrease is due to reduced costs for personnel, consulting fees, clinical trials and production, and business development.

Depreciation and impairment of tangible and intangible assets during the first quarter of 2025 amounted to SEK 0.0 (-0.6) MSEK. Due to the board of directors' decision to write down the carrying amounts of all intangible assets as of the closing date of 2024-12-31, the first quarter is not burdened by any further depreciation or impairment.

The equity ratio for the Group amounted to 59 percent on March 31 2025 and equity to 3.2 MSEK.

Due to cost and personnel reductions implemented and other decisions made during April, the Board of Directors' assessment is that the Group's cash will be sufficient throughout 2025, provided that the company's operations continue to be conducted at the current level. Should the cost level increase during 2025, additional financing will be required earlier.

Auxiliary information

LIDDS share

LIDDS share is listed on Nasdaq First North Growth Market in Stockholm since 2014 with ticker LIDDS and ISIN code SE0001958612. Since the 18 July 2024, the trading is done through an auction five times per day. This is due to a spread in the share trading was higher than 7% during the first two quarters 2024.

Following the board's decision to cease further development of the Nanodotax, Nanoimodand NOV 202 project areas on April 2, Nasdaq announced that the share has been given observation status. The observation status was also updated on April 22 following the decision to prepare a balance sheet for liquidation purposes for the company.

The number of shares as of January 1, 2025 was 136,463,326 (68,231,663) and as of March 31, 2025 was 136,463,326 (136,463,326). The average number of shares during the first quarter of 2025 was 136,463,326 (77,784,096).

The company's largest shareholders on 31 March 2025

| Shareholders | Number of shares | Share of capital and votes (%) |
|---|--------------------|--------------------------------|
| Daniel Lifveredson, incl shares owned through companies | 28 029 909 | 20,5 |
| Avanza Pension | 9 817 054 | 7,2 |
| Ove Högberg | 8 562 191 | 6,3 |
| Marita Högberg | 6 851 116 | 5,0 |
| Stefan Rehnmark | 6 632 971 | 4,9 |
| Wikow Invest AB | 6 196 517 | 4,5 |
| Torbjörn Browall, incl shares owned through companies | 4 614 519 | 3,4 |
| Torbjörn Browall, inkl aktier ägda via bolag | 3 600 000 | 2,6 |
| Skyshire AB | 3 129 017 | 2,3 |
| Anders Bjartell | 2 605 389 | 1,9 |
| Swedbank Försäkring | 1 938 675 | 1,4 |
| Other shareholders | 54 485 968 | 39,9 |
| Total | 136 463 326 | 100,0 |

Personnel and organization

At the end of March 2025, the number of employees was one.

Financial calendar

Interim Report January – June

28 August 2025

Interim Report January – September

20 November 2025

Transactions with related parties

The company has not had any transactions with related parties in the first quarter 2025 other than decided fees and remuneration for the board and management and that the company rents a workplace from Excore AB at Kungssportsavenyen 22 in Gothenburg, which is also the company's address since September 2024.

Uncertainty regarding going concern

The combination of the board's decision to cease the development of three project areas, the write-down of all intangible assets and the preparation of a balance sheet for liquidation purposes means that there is significant uncertainty regarding the continued operation of the company's operations.

Significant risks and uncertainties

Apart from general uncertainties related to the sale of the assets in LIDDS AB and Noviga Research AB, there are no known tendencies, uncertainties, potential liabilities and obligations, commitments or events that can be expected to have a significant impact on the company's future prospects.

Parent company

The acquisition of Noviga Research AB was classified as a reverse takeover and Noviga is parent company in the group accounts. The legal parent company is still LIDDS.

Review by auditor

This report has not been reviewed by the company's auditor.

Assurance by the Board of Directors

The Board of Directors and the CEO confirm that this interim report provides a fair view of the operations, financial position and results for the parent company and the group and describes the significant risks and uncertainties that the company and the companies in the group are exposed to.

Göteborg 28 May 2025

LIDDS AB (publ) Board of Directors

Daniel Lifveredson
Ordförande

Torbjörn Browall

Stefan Rehnmark

Lars-Inge Sjöqvist

Mats Wiking
VD

Group Income statement

| KSEK | 1 January - 31 March 2025 | 1 January - 31 March 2024 | 1 January - 31 December 2024 |
|---|------------------------------|------------------------------|---------------------------------|
| Operating income | | | |
| Net sales | 0 | 0 | 0 |
| Capitalised work on own account | 0 | 23 | 32 |
| Other operating income | 0 | 903 | 977 |
| Total | 0 | 926 | 1 009 |
| Operating expenses | | | |
| External operating expenses | -942 | -215 | -3 437 |
| Personnel costs | -313 | -112 | -1 556 |
| Depreciation and impairment of fixed assets | 0 | -600 | -1 901 |
| Other operating costs | 0 | 0 | -5 |
| Total | -1 254 | -927 | -6 900 |
| Operating result | -1 254 | -1 | -5 891 |
| Financial income | 26 | 0 | 307 |
| Financial expenses | -82 | -4 | -101 |
| Total | -56 | -4 | 207 |
| Result after financial items | -1 311 | -5 | -5 684 |
| Result before tax | -1 311 | -5 | -5 684 |
| Tax | 0 | 0 | -254 |
| Result for the period | -1 311 | -5 | -5 938 |

Group Balance sheet

| KSEK | Note | 31 March 2025 | 31 March 2024 | 31 December 2024 |
|-------------------------------------|------|---------------|---------------|------------------|
| ASSETS | | | | |
| Fixed assets | | | | |
| Intangible assets | | | | |
| Capitalized development expenditure | | 0 | 0 | 0 |
| Patents | | 0 | 1 204 | 0 |
| Total | | 0 | 1 204 | 0 |
| Tangible assets | | | | |
| Property, plant and equipment | | 0 | 25 | 0 |
| Total | | 0 | 25 | 0 |
| Financial assets | | | | |
| Deferred tax assets | | 0 | 254 | 0 |
| Total | | 0 | 254 | 0 |
| Total non-current assets | | 0 | 1 482 | 0 |
| Current assets | | | | |
| Current receivables | | | | |
| Trade receivables | | 0 | 0 | 0 |
| Receivables at suppliers | | 0 | 0 | 0 |
| Current tax receivables | | 0 | 368 | 804 |
| Other current receivables | | 542 | 274 | 59 |
| Prepaid expenses and accrued income | | 162 | 593 | 162 |
| Total | | 705 | 1 235 | 1 025 |
| Cash and cash equivalents | | 4 768 | 10 947 | 5 506 |
| Total current assets | | 5 473 | 12 182 | 6 531 |
| TOTAL ASSETS | | 5 473 | 13 665 | 6 531 |

Group Balance sheet

| KSEK | Note | 31 March 2025 | 31 March 2024 | 31 December 2024 |
|---|------|---------------|---------------|------------------|
| EQUITY AND LIABILITIES | | | | |
| Equity | | | | |
| Share capital | | 7 233 | 7 233 | 7 233 |
| Additional paid-in capital | | 3 629 | 3 629 | 3 629 |
| Retained earnings (including loss for the period) | | -7 620 | -677 | -6 309 |
| Total equity attributable to Parent Company shareholders | | 3 241 | 10 185 | 4 552 |
| Long-term liabilities | | | | |
| Other liabilities | | 715 | 900 | 0 |
| | | 715 | 900 | 0 |
| Current liabilities | | | | |
| Trade payables | | 308 | 1 072 | 459 |
| Other current liabilities | | 28 | 113 | 664 |
| Accrued expenses and deferred income | | 1 180 | 1 395 | 856 |
| Total | | 1 516 | 2 580 | 1 979 |
| TOTAL EQUITY AND LIABILITIES | | 5 472 | 12 765 | 6 531 |

Consolidated statement of changes in equity

| KSEK | Attributable to the Parent Company shareholders | | | Total equity |
|--------------------------------------|---|---------------------------|---|--------------|
| | Share capital | Other contributed capital | Retained earnings, incl compr income for the period | |
| Opening balance 1 January, 2025 | 7 233 | 3 629 | -6 309 | 4 552 |
| Transactions with shareholders | | | | |
| Share issue | 0 | 0 | 0 | 0 |
| Reverse takeover effect | 0 | 0 | 0 | 0 |
| Shareholder's contribution | 0 | 0 | 0 | 0 |
| Result for the period | 0 | 0 | -1 311 | -1 311 |
| Total transactions with shareholders | 0 | 0 | -1 311 | -1 311 |
| Closing balance 31 March, 2025 | 7 233 | 3 629 | -7 620 | 3 241 |

Group Cash flow statement

| KSEK | 1 January - 31 March 2025 | 1 January - 31 March 2024 | 1 January - 31 December 2024 |
|--|------------------------------|------------------------------|---------------------------------|
| Operating activities | | | |
| Operating profit/loss before financial items | -1 254 | -1 | -5 890 |
| Interest received | 26 | 0 | 307 |
| Interest paid | -50 | -4 | -2 |
| <i>Adjustments for non-cash items</i> | | | |
| Depreciation and Impairment of intangible and tangible assets | 0 | -302 | 998 |
| Cash flow from operating activities before changes in working capital | -1 279 | -308 | -4 588 |
| Cash flow from changes in working capital | | | |
| Change in operating receivables | 320 | 88 | 298 |
| Change in operating liabilities | 220 | 156 | -1 145 |
| Cash flow from operating activities | -738 | -64 | -5 434 |
| Investing activities | | | |
| Acquisition of intangible assets | 0 | -23 | -94 |
| Acquisition of tangible assets | 0 | 0 | 0 |
| Cash flow from investing activities | 0 | -23 | -94 |
| Financing activities | | | |
| Share issue | 0 | 0 | 0 |
| Issuance costs | 0 | -280 | -280 |
| Subscription warrants | 0 | 0 | 0 |
| Net borrowings | 0 | 0 | 0 |
| Payment convertible loan | 0 | 0 | 0 |
| Cash flow from financing activities | 0 | -280 | -280 |
| Net cash flow for the period | -738 | -367 | -5 809 |
| Cash and cash equivalents at the beginning of the period | 5 506 | 191 | 191 |
| Cash and cash equivalents in acquired subsidiary | 0 | 11 124 | 11 124 |
| Cash and cash equivalents at the end of the period | 4 768 | 10 947 | 5 505 |

Income statement Parent company

| KSEK | 1 januari - 31 mars 2025 | 1 januari - 31 mars 2024 | 1 januari - 31 december 2024 |
|---|-----------------------------|-----------------------------|---------------------------------|
| Rörelsens intäkter | | | |
| Nettoomsättning | 0 | 0 | 0 |
| Aktiverat arbete för egen räkning | 0 | 36 | 45 |
| Övriga rörelseintäkter | 0 | 0 | 61 |
| Summa | 0 | 36 | 106 |
| Rörelsens kostnader | | | |
| Övriga externa kostnader | -799 | -1 281 | -4 309 |
| Personalkostnader | -313 | -626 | -2 070 |
| Av-/nedskrivning av immateriella och materiella anläggningstillgångar | 0 | -598 | -1 906 |
| Övriga rörelsekostnader | 0 | 0 | -5 |
| Summa | -1 111 | -2 505 | -8 290 |
| Rörelseresultat | -1 111 | -2 470 | -8 185 |
| Nedskrivning andel i dotterbolag | 0 | 0 | -11 457 |
| Ränteintäkter | 26 | 27 | 334 |
| Räntekostnader | 0 | -1 | -3 |
| Summa | 26 | 25 | -11 127 |
| Resultat efter finansiella poster | -1 086 | -2 444 | -19 312 |
| Resultat före skatt | -1 086 | -2 444 | -19 312 |
| Periodens resultat | -1 086 | -2 444 | -19 312 |

Balance sheet parent company

| KSEK | 31 March 2025 | 31 March 2024 | 31 December 2024 |
|-------------------------------------|---------------|---------------|------------------|
| ASSETS | | | |
| Fixed assets | | | |
| Intangible assets | | | |
| Capitalized development expenditure | 0 | 0 | 0 |
| Patents | 0 | 1 231 | 0 |
| Total | 0 | 1 231 | 0 |
| Tangible assets | | | |
| Property, plant and equipment | 0 | 5 | 0 |
| Total | 0 | 5 | 0 |
| Financial assets | | | |
| Shares in group companies | 200 | 10 307 | 200 |
| Total | 200 | 10 307 | 200 |
| Total non-current assets | 200 | 11 543 | 200 |
| Current assets | | | |
| Current receivables | | | |
| Trade receivables | 0 | 0 | 0 |
| Receivables group companies | 201 | 45 | 0 |
| Current tax receivables | 489 | 368 | 690 |
| Other current receivables | 1 | 274 | 151 |
| Prepaid expenses and accrued income | 162 | 593 | 162 |
| Total | 853 | 1 280 | 1 003 |
| Cash and cash equivalents | 4 680 | 10 847 | 5 394 |
| Total current assets | 5 533 | 12 128 | 6 396 |
| TOTAL ASSETS | 5 733 | 23 670 | 6 596 |

Balance sheet parent company

| KSEK | 31 mars 2025 | 31 mars 2024 | 31 december 2024 |
|--|----------------|---------------|------------------|
| EGET KAPITAL OCH SKULDER | | | |
| Eget kapital | | | |
| Bundet eget kapital | | | |
| Aktiekapital | 7 233 | 7 233 | 7 233 |
| Reservfond | 15 223 | 15 223 | 15 223 |
| Fond för utvecklingsutgifter | 0 | 0 | 0 |
| Summa | 22 456 | 22 456 | 22 456 |
| Fritt eget kapital | | | |
| Överkursfond | 356 502 | 356 502 | 356 502 |
| Balanserat resultat (inklusive årets resultat) | -375 553 | -357 599 | -374 467 |
| Summa | -19 052 | -1 098 | -17 966 |
| Summa eget kapital | 3 404 | 21 358 | 4 490 |
| Kortfristiga skulder | | | |
| Leverantörsskulder | 187 | 821 | 290 |
| Skulder till koncernföretag | 1 035 | 26 | 1 035 |
| Övriga kortfristiga skulder | 28 | 109 | 23 |
| Upplupna kostnader | 1 080 | 1 356 | 758 |
| Summa | 2 329 | 2 312 | 2 106 |
| SUMMA EGET KAPITAL OCH SKULDER | 5 733 | 23 670 | 6 596 |

Notes

Accounting principles

From 1 January 2024 LIDDS apply K3 as accounting principle. The change from IFRS to K3 has not had any significant effects on the group's equity, reporting forms or disclosures.

Acquisition analysis

In January 2024, it was announced that an agreement had been signed to acquire Noviga Research AB. The acquisition was approved at an extraordinary general meeting of LIDDS on 27 February 2024. LIDDS acquired all shares in Noviga Research AB through a issue in kind. The acquisition has been classified as a reverse acquisition, which means that the former owners of Noviga Research AB gain the controlling influence over LIDDS. Through the reverse acquisition Noviga Research AB is considered to be the acquirer and also the parent company in the group for accounting purposes. The purchase price amounted to 10.5 MSEK, corresponding to 68,231,663 shares in LIDDS. The negative goodwill that arises as an effect of the acquisition amounts to 912,000 SEK has been reported as other operating income. Due to the fact that Noviga Research AB was not a parent company in the group before the acquisition of LIDDS, there are no comparison periods for the group. The group was formed on March 7, 2024, and results and cash flow are calculated in the group as of this date. Earnings per share is calculated as the group's net profit divided by the average number of shares during the period March 7 – March 31, 136,463,326.

For further information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)706 200400
E-mail: mats.wiking@liddspharma.com

LIDDS AB (publ)
Kungsportsavenyen 22
411 36 GÖTEBORG

www.liddspharma.com

Corporate registration number: 556580–2856